Medasense, a pioneer in pain monitoring technology, has announced a strategic agreement with Panakeia, LLC, a Service-Disabled Veteran-Owned Small Business and a leading healthcare solutions provider, to distribute Medasense’s PMD-200 device to United States government institutions.
The agreement comes as part of Panakeia’s commitment to providing state-of-the-art, innovative medical solutions to enhance patient care, particularly in military healthcare settings. The PMD-200 with NOL – Nociception Level Index® is the first FDA-authorized device designed to objectively monitor a patient’s pain response under general anesthesia, enabling healthcare professionals to personalize pain management and improve patient outcomes.
Read the full press release here.
